(Total Views: 493)
Posted On: 03/05/2021 11:51:19 AM
Post# of 153874
Not sure if this was posted, but another potential treatment bites the dust...
Apellis Shelves Study Of APL-9 In Severe COVID-19 Patients
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) said it will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee, which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.
Apellis Shelves Study Of APL-9 In Severe COVID-19 Patients
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) said it will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee, which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.
(3)
(0)
